Please assess the completion status of the following clinical trial:

Trial Title: Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ulcerative colitis (UC) established ≥ 3 months before baseline by clinical and endoscopic evidence and corroborated by a histopathology report.~* Moderate to severe active UC as defined by a total Mayo score of 6 to 12 with a centrally read rectosigmoidoscopy score ≥2 prior to baseline~* Inadequate response to, loss of response to, or intolerance to at least one of the following treatments:~  * Immunomodulators~ * Anti-TNF agents~ * Corticosteroids (non-US sites only).~* Neurological exam free of clinically significant, unexplained signs or symptoms during screening and no clinically significant change prior to randomization~Exclusion Criteria:~* Disease limited to the rectum (ie, within 10 cm of the anal verge)~* Toxic megacolon~* Crohn's Disease~* History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for UC~* Planned bowel surgery within 24 weeks from baseline~* Stool positive for C. Difficile toxin at screening~* History of gastrointestinal surgery within 8 weeks of baseline~* Primary Sclerosing Cholangitis~* Any uncontrolled or clinically significant systemic disease~* Condition or disease that, in the opinion of the investigator would pose a risk to subject safety or interfere with study evaluation, procedures or completion.~* Known to have tested positive for hepatitis B virus surface antigen, hepatitis C virus antibody or human immunodeficiency virus (HIV)~* Underlying condition that predisposes subject to infections (eg, uncontrolled diabetes; history of splenectomy)~* Known history of drug or alcohol abuse within 1 year of screening~* Malignancy (other than resected cutaneous basal or cutaneous squamous cell carcinoma, or treated in situ cervical cancer considered cured) within 5 years of screening visit (if a malignancy occurred \> 5 years ago, subject is eligible with documentation of disease free state since treatment)~* Immunosuppressive therapy with either cyclosporine A, tacrolimus, or mycophenolate mofetil, within 1 month prior to baseline~* Prior exposure to anti tumor necrosis factor (TNF) agents, within 2 months, or 5 times the respective elimination half life (whichever is longer) prior to baseline~* Any prior exposure to vedolizumab, rituximab, efalizumab, natalizumab~* Use of topical (rectal) aminosalicylic acid (eg, mesalamine) or topical (rectal) steroids within 2 weeks prior to baseline~* Use of intravenous or intramuscular corticosteroids within 2 weeks prior to screening and during screening~* Previously treated with AMG 181~* Received any type of live attenuated vaccine \< 1 month prior to baseline or is planning to receive any such live attenuated vaccine over the course of the study~* Treatment of infection with intravenous (within 30 days of baseline) or oral (within 14 days prior to baseline) antibiotics, antivirals, or antifungals~* Abnormal laboratory results at screening~* Any other laboratory abnormality, which, in the opinion of the investigator, will prevent the subject from completing the study or will interfere with the interpretation of the study results~* Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Q4W/Abrilumab 210 mg Q3M (Type: PLACEBO_COMPARATOR): Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks.
- Abrilumab 7 mg Q4W/Abrilumab 210 mg Q3M (Type: EXPERIMENTAL): Participants received 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks.
- Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M (Type: EXPERIMENTAL): Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks.
- Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M (Type: EXPERIMENTAL): Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks.
- Abrilumab 210 mg/Abrilumab 210 mg Q3M (Type: EXPERIMENTAL): Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).